In extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy meaningfully extended survival. @DanaFarber's Jacob Sands, MD, presents in the #ESMO26 Presidential Symposium.
Read more: https://bit.ly/4yz9ntL
37 views · 0 likes · 0 reposts · 0 replies
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Dana-Farber News · x.com